AngioDynamics Inc (ANGO)
6.12
-0.21
(-3.32%)
USD |
NASDAQ |
Apr 18, 16:00
6.115
0.00 (0.00%)
After-Hours: 20:00
AngioDynamics Research and Development Expense (Quarterly): 8.189M for Feb. 29, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| February 29, 2024 | 8.189M |
| November 30, 2023 | 8.658M |
| August 31, 2023 | 7.941M |
| May 31, 2023 | 7.86M |
| February 28, 2023 | 6.852M |
| November 30, 2022 | 6.838M |
| August 31, 2022 | 8.333M |
| May 31, 2022 | 7.866M |
| February 28, 2022 | 7.28M |
| November 30, 2021 | 8.199M |
| August 31, 2021 | 7.394M |
| May 31, 2021 | 9.104M |
| February 28, 2021 | 8.565M |
| November 30, 2020 | 9.712M |
| August 31, 2020 | 9.009M |
| May 31, 2020 | 7.232M |
| February 29, 2020 | 8.395M |
| November 30, 2019 | 7.764M |
| August 31, 2019 | 6.292M |
| May 31, 2019 | 6.893M |
| February 28, 2019 | 6.915M |
| November 30, 2018 | 7.076M |
| August 31, 2018 | 7.374M |
| May 31, 2018 | 5.333M |
| February 28, 2018 | 6.457M |
| Date | Value |
|---|---|
| November 30, 2017 | 6.107M |
| August 31, 2017 | 6.441M |
| May 31, 2017 | 5.575M |
| February 28, 2017 | 5.951M |
| November 30, 2016 | 5.913M |
| August 31, 2016 | 6.709M |
| May 31, 2016 | 6.937M |
| February 29, 2016 | 5.808M |
| November 30, 2015 | 6.179M |
| August 31, 2015 | 6.129M |
| May 31, 2015 | 6.952M |
| February 28, 2015 | 6.855M |
| November 30, 2014 | 6.069M |
| August 31, 2014 | 6.718M |
| May 31, 2014 | 7.367M |
| February 28, 2014 | 7.045M |
| November 30, 2013 | 7.003M |
| August 31, 2013 | 6.709M |
| May 31, 2013 | 6.438M |
| February 28, 2013 | 5.793M |
| November 30, 2012 | 7.014M |
| August 31, 2012 | 7.074M |
| May 31, 2012 | 5.222M |
| February 29, 2012 | 4.574M |
| November 30, 2011 | 5.125M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
6.292M
Minimum
Aug 2019
9.712M
Maximum
Nov 2020
7.919M
Average
7.904M
Median
Research and Development Expense (Quarterly) Benchmarks
| Becton Dickinson & Co | 290.00M |
| Integer Holdings Corp | 13.26M |
| Outset Medical Inc | 12.53M |
| Perspective Therapeutics Inc | 6.08M |
| Xtant Medical Holdings Inc | 0.492M |